Bruker Corporation (BRKR)
NASDAQ: BRKR · Real-Time Price · USD
61.35
-2.51 (-3.93%)
Oct 6, 2026, 12:50 PM EDT - Market open
Bruker Revenue
Bruker had revenue of $838.50M in the quarter ending June 30, 2026, with 5.15% growth. This brings the company's revenue in the last twelve months to $3.50B, up 1.65% year-over-year. In the year 2025, Bruker had annual revenue of $3.44B with 2.08% growth.
Revenue (ttm)
$3.50B
Revenue Growth
+1.65%
P/S Ratio
2.65
Revenue / Employee
$315,706
Employees
11,085
Market Cap
9.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.44B | 70.10M | 2.08% |
| Dec 31, 2024 | 3.37B | 401.90M | 13.56% |
| Dec 31, 2023 | 2.96B | 433.80M | 17.14% |
| Dec 31, 2022 | 2.53B | 112.80M | 4.67% |
| Dec 31, 2021 | 2.42B | 430.40M | 21.66% |
| Dec 31, 2020 | 1.99B | -85.10M | -4.11% |
| Dec 31, 2019 | 2.07B | 177.00M | 9.34% |
| Dec 31, 2018 | 1.90B | 129.70M | 7.34% |
| Dec 31, 2017 | 1.77B | 154.60M | 9.59% |
| Dec 31, 2016 | 1.61B | -12.50M | -0.77% |
| Dec 31, 2015 | 1.62B | -185.10M | -10.23% |
| Dec 31, 2014 | 1.81B | -30.50M | -1.66% |
| Dec 31, 2013 | 1.84B | 48.00M | 2.68% |
| Dec 31, 2012 | 1.79B | 139.70M | 8.46% |
| Dec 31, 2011 | 1.65B | 346.80M | 26.58% |
| Dec 31, 2010 | 1.30B | 190.40M | 17.08% |
| Dec 31, 2009 | 1.11B | 7.40M | 0.67% |
| Dec 31, 2008 | 1.11B | 74.70M | 7.24% |
| Dec 31, 2007 | 1.03B | 181.00M | 21.26% |
| Dec 31, 2006 | 851.40M | 479.15M | 128.72% |
| Dec 31, 2005 | 372.25M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| STERIS | 6.04B |
| Globus Medical | 3.14B |
| Insulet | 3.05B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
| Penumbra | 1.50B |
BRKR News
- 5 hours ago - Bruker announces seminal bioRxiv preprint - TheFly
- 5 hours ago - Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution - Business Wire
- 5 days ago - Bruker price target raised to $72 from $70 at Guggenheim - TheFly
- 7 days ago - Bruker price target raised to $80 from $60 at Leerink - TheFly
- 8 days ago - Bruker announces timsUltra AIP, timsOmni workflows for drug discovery - TheFly
- 8 days ago - Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research - Business Wire
- 14 days ago - Bruker Transcript: Bank of America Global Healthcare Conference - Transcripts
- 15 days ago - Bruker announces over $6M multi-system order from UC Berkeley - TheFly